PMID- 30541217
OWN - NLM
STAT- MEDLINE
DCOM- 20190305
LR  - 20190305
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 98
IP  - 46
DP  - 2018 Dec 11
TI  - [Effects of berberine on the serum cystatin C levels and urine albumin/creatine 
      ratio in patients with type 2 diabetes mellitus].
PG  - 3756-3761
LID - 10.3760/cma.j.issn.0376-2491.2018.46.007 [doi]
AB  - Objective: To investigate the effects of berberine on urine albumin/creatine 
      ratio (UACR) and serum cystatin C (Cys C) in patients with type 2 diabetes 
      mellitus (T2DM). Methods: A total of 114 T2DM inpatients or outpatients, 
      including 46 males and 68 females aged (55+/-14) years between January 2015 and 
      January 2016 were randomly divided into two groups: the control group (n=57) only 
      with hypoglycemic agents, and the intervention group (n=57) with berberine (0.4 
      g, 3 times a day) on the basis of treatment from the control group. Both groups 
      were treated and followed up for six months. All the clinical and biochemical 
      parameters were routinely evaluated before and after treatment. And the safety of 
      berberine was assessed. Results: After the treatment, the improvement of 
      glycosylated hemoglobin (HbA1c), blood urea nitrogen (BUN), systolic pressure 
      (SP), high sensitive C-reactive protein (hs-CRP), rythrocyte sedimentation rate 
      (ESR), estimated glomerular filtration rate (eGFR) in the intervention group were 
      significantly better than those in the control group (all P<0.05), as well as the 
      UACR[47(26, 120) mg/g vs 103(42, 267) mg/g, P<0.001]and serum Cys C[(0.83+/-0.30) 
      mg/L vs (0.98+/-0.25) mg/L, P=0.031]. However, there was no statistically 
      significant difference of UACR and Cys C between before and after treatment in 
      the control group (all P>0.05). Compared to the control group, the patients in 
      the intervention group had lesser UACR[47(26, 120) mg/g vs 68(28, 158) mg/g, 
      P=0.039], and lower serum Cys C[(0.83+/-0.30) mg/L vs (0.96+/-0.30)mg/L, P=0.041]. 
      Berberine had no obvious adverse effects. Multiple linear regression analysis 
      revealed that the berberine administration was independently associated with the 
      reduction of UACR (beta=-0.051, P=0.041) and Cys C (beta=-0.068, P=0.033) in T2DM 
      patients. Conclusion: Berberine improves diabetic kidney disease by reducing UACR 
      and serum Cys C in T2DM patients, and it was safe.
FAU - Li, Z Y
AU  - Li ZY
AD  - Department of Endocrinology and Metabolism, Jinshan Branch, Shanghai Sixth 
      People's Hospital, Shanghai 201599, China.
FAU - Liu, B
AU  - Liu B
FAU - Zhuang, X J
AU  - Zhuang XJ
FAU - Shen, Y D
AU  - Shen YD
FAU - Tian, H R
AU  - Tian HR
FAU - Ji, Y
AU  - Ji Y
FAU - Li, L X
AU  - Li LX
FAU - Liu, F
AU  - Liu F
LA  - chi
GR  - 2014-3-25/Shanghai Jinshan Science and Technology Innovation Fund Program/
GR  - 20152232/Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant 
      Support/
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Albumins)
RN  - 0 (Cystatin C)
RN  - 0I8Y3P32UF (Berberine)
RN  - AYI8EX34EU (Creatinine)
RN  - MU72812GK0 (Creatine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Albumins
MH  - Albuminuria
MH  - Berberine
MH  - Creatine
MH  - Creatinine
MH  - Cystatin C
MH  - *Diabetes Mellitus, Type 2
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
OTO - NOTNLM
OT  - Berberine
OT  - Cystatin C
OT  - Diabetes mellitus, type 2
OT  - Urine albumin/creatine ratio
EDAT- 2018/12/14 06:00
MHDA- 2019/03/06 06:00
CRDT- 2018/12/13 06:00
PHST- 2018/12/13 06:00 [entrez]
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2019/03/06 06:00 [medline]
AID - 10.3760/cma.j.issn.0376-2491.2018.46.007 [doi]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2018 Dec 11;98(46):3756-3761. doi: 
      10.3760/cma.j.issn.0376-2491.2018.46.007.